NurExone to Present on Revolutionary Spinal Cord Injury Therapy at European Conference on Exosomes and Regenerative Medicine

Depiction of exosome

On April 19, 2024, NurExone Biologic Inc. (TSXV: NRX) (Germany: J90) a pioneering biopharmaceutical company, was pleased to announce that Dr. Lior Shaltiel, CEO and Director at NurExone, has been invited to present on "Revolutionizing Spinal Cord Injury Treatment: Harnessing the Potential of Exosomes for Advanced Therapy in Comprehensive Approach" at the Exosomes Europe conference in London in June 2024. Dr. Shaltiel joins a prestigious lineup of speakers presenting applications of exosomes, including representatives from leading exosome companies such as Abbvie, Evox Therapeutics, and Capricor Therapeutics, as well as senior-level executives in the field. As a pioneer and leader in this field, Dr. Shaltiel is well-positioned to provide perspective on exploiting advances in exosomes for drug delivery. NurExone is developing a first exosome-loaded nanodrug, ExoPTEN, for patients who suffer acute spinal cord injuries.

Login Or Register To Read Full Story